Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications
Matching-Adjusted Indirect Comparison of Risankizumab Versus Icotrokinra in Adult Patients with Moderate-to-Severe Plaque Psoriasis.
Journal: Dermatology and therapy
Published: April 29, 2026
Speed and Cumulative Responses According to Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Ixekizumab (Interleukin-17A Antagonist) versus Guselkumab (Interleukin-23p19 Inhibitor).
Journal: Dermatology and therapy
Published: September 11, 2023
Efficacy of long-term risankizumab treatment for moderate-to-severe plaque psoriasis: Subgroup analyses by baseline characteristics and psoriatic disease manifestations through 256 weeks (LIMMitless trial).
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: August 15, 2023
Safety of guselkumab in patients with psoriasis with a history of malignancy: 5-year results from the VOYAGE 1 and VOYAGE 2 trials.
Journal: The British journal of dermatology
Published: January 13, 2023
Switching to risankizumab from ustekinumab or adalimumab in plaque psoriasis patients improves PASI and DLQI outcomes for sub-optimal responders.
Journal: The Journal of dermatological treatment
Published: July 15, 2022
Healthcare Providers Face Numerous Challenges in Treating Patients with Psoriasis: Results from a Mixed-Methods Study.
Journal: Journal of psoriasis and psoriatic arthritis
Published: January 01, 2022
Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study.
Journal: Dermatology and therapy
Published: November 05, 2021
A brief guide to pustular psoriasis for primary care providers.
Journal: Postgraduate medicine
Published: October 29, 2020
Sustained and continuously improved efficacy of tildrakizumab in patients with moderate-to-severe plaque psoriasis.
Journal: The Journal of dermatological treatment
Published: July 04, 2019
Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial.
Journal: Lancet (London, England)
Published: November 20, 2018
Improvements in psoriasis within different body regions vary over time following treatment with ixekizumab.
Journal: The Journal of dermatological treatment
Published: August 10, 2017
Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial.
Journal: Journal of the American Academy of Dermatology
Published: March 09, 2017
Last Updated: 09/26/2026